Drug intelligence / Profile preview

[177Lu]RadioEVs

Development stage
Preclinical
Lead developer
Instituto de Investigación Sanitaria Gregorio Marañón
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

[177Lu]RadioEVs (also known as [177Lu]RadioExo) is a preclinical nanotheranostic agent consisting of goat milk-derived extracellular vesicles (EVs) radiolabeled with Lutetium-177 (177Lu) via passive membrane loading or DOTA-mediated chelation. Developed by the Instituto de Investigación Sanitaria Gregorio Marañón and the Universidad Carlos III de Madrid, this radiopharmaceutical leverages the natural tumor tropism and biocompatibility of milk-derived exosomes to deliver targeted beta-radiation directly to cancer cells. In preclinical studies, [177Lu]RadioEVs demonstrated efficient tumor-targeted internalization and dose-dependent cytotoxicity in various cancer cell lines, including glioblastoma (U87MG), breast cancer (MDA-MB-231), colorectal cancer (HCT116), pancreatic cancer (PANC1), and cutaneous melanoma, while serving as a SPECT imaging agent for real-time tumor localization.

Other names
177Lu-labeled extracellular vesicles177Lu-labeled exosomes[177Lu]EVs[177Lu]FluoEVs[177Lu]RadioExo[177Lu]RadioExosomes
02

Identity

Drug type
Blood, Tissue and Cell-Derived Products
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma EmittersLipid-based Nanoparticles
03

Pharmacology

Targets

Route
Intravenous
04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
colorectal cancer (CRC) and precursor lesionsPreclinicalActive
glioblastoma, IDH-wildtypePreclinicalActive
melanomaPreclinicalActive
pancreatic cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Instituto de Investigación Sanitaria Gregorio MarañónLead developer
07

Competitive landscape

Drugs on the same target
280
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. fluorouracilApproved
  4. thiotepaApproved
  5. bleomycinApproved

Beyond the preview

Go deeper on [177Lu]RadioEVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [177Lu]RadioEVs.

Work on [177Lu]RadioEVs? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call